Platelet activation, and antiplatelet targets and agents: Current and novel strategies

Drugs

Volumn 68, Issue 12, 2008, Pages 1647-1664

  Xiang, Yao Zu ^a   Xia, Ye ^a   Gao, Xiu Mei ^a   Shang, Hong Cai ^a   Kang, Li Yuan ^a   Zhang, Bo Li ^a  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Abciximab, therapeutic use; Antiplatelets, therapeutic use; Aspirin, therapeutic use; Cilostazol, therapeutic use; Clopidogrel, therapeutic use; Dipyridamole, therapeutic use; Thrombosis, treatment; Triflusal, therapeutic use

Indexed keywords

2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; EXP 3179; FIBRINOGEN; GUANINE NUCLEOTIDE BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; INS 50589; LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PRASUGREL; PROSTACYCLIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; REGRELOR; RIDOGREL; SARPOGRELATE; SEROTONIN; TERUTROBAN; THROMBIN; THROMBOXANE A2; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG DESIGN; DRUG RESEARCH; DRUG TARGETING; GENETIC POLYMORPHISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE; NONHUMAN; RECEPTOR BLOCKING; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

DRUG DESIGN; HUMANS; META-ANALYSIS AS TOPIC; MODELS, BIOLOGICAL; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION;

EID: 49249127272     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868120-00004     Document Type: Review

References (140)

1. Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004; 114 (5-6): 447-53
2. Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets 2001; 12 (5): 261-73
3. Lasne D, Jude B, Susen S. From normal to pathological hemostasis. Can J Anaesth 2006; 53 (6 Suppl.): S2-11
4. Jagroop IA, Kakafika AI, Mikhailidis DP. Platelets and vascular risk: an option for treatment. Curr Pharm Des 2007; 13 (16): 1669-83
5. Williams MS, Bray PF. Genetics of arterial prothrombotic risk states. Exp Biol Med (Maywood) 2001; 226 (5): 409-19
6. Ouwehand WH, for the Bloodomics and Wellcome Trust Case Control Consortia. Platelet genomics and the risk of atherothrombosis. J Thromb Haemost 2007; 5 Suppl. 1: 188-95
7. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334 (17): 1090-4
8. Yee DL, Bray PF. Clinical and functional consequences of platelet membrane glycoprotein polymorphisms. Semin Thromb Hemost 2004; 30 (5): 591-600
9. Yee DL, Bergeron AL, Sun CW, et al. Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost 2006; 4 (9): 2043-50
10. Lev EI, Patel RT, Guthikonda S, et al. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 2007; 119 (3): 355-60
11. Lepäntalo A, Mikkelsson J, Reséndiz JC, et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006; 95 (2): 253-9
12. Cipollone F, Toniato E, Martinotti S, et al. Identification of New Elements of Plaque Stability (INES) Study Group. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction or stroke. JAMA 2004; 291 (18): 2221-8
13. Macchi L, Christiens L, Brabant S, et al. Resistance in vitro to low dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003; 42 (6): 1115-9
14. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108 (7): 2244-7
15. Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006; 174 (12): 1715-22
16. Turgeon J, Pharand C, Michaud V. Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism. CMAJ 2006; 174 (12): 1729
17. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5 (12): 2429-36
18. Bigalke B, Langer H, Geisler T, et al. Platelet glycoprotein VI: a novel marker for acute coronary syndrome. Semin Thromb Hemost 2007; 33 (2): 179-84
19. Smith T, Dhunnoo G, Mohan I, et al. A pilot study showing an association between platelet hyperactivity and the severity of peripheral arterial disease. Platelets 2007; 18 (4): 245-8
20. Rajagopalan S, Mckay I, Ford I, et al. Platelet activation increases with the severity of peripheral arterial disease: Implications for clinical management. J Vasc Surg 2007; 46 (3): 485-90
21. Bray PF. Platelet hyperreactivity: predictive and intrinsic properties. Hematol Oncol Clin North Am 2007; 21 (4): 633-45
22. Osmancik PP, Bednar F, Móciková H. Glycemia, triglycerides and disease severity are best associated with higher platelet activity in patients with stable coronary artery disease. J Thromb Thrombolysis 2007; 24 (2): 105-7
23. Korporaal SJ, Akkerman JW. Platelet activation by low density lipoprotein and high density lipoprotein. Pathophysiol Haemost Thromb 2006; 35 (3-4): 270-80
24. Nofer JR, Noll C, Feuerborn R, et al. Low density lipoproteins inhibit the Na+/H+ antiport in human platelets via activation of p38MAP kinase. Biochem Biophys Res Commun 2006; 340 (3): 751-7
25. Hackeng CM, Pladet MW, Akkerman JW, et al. Low density lipoprotein phosphorylates the focal adhesion-associated kinase p125(FAK) in human platelets independent of integrin alphaIIb beta3. J Biol Chem 1999; 274 (1): 384-8
26. Menys VC, Bhatnagar D, Mackness MI, et al. Spontaneous platelet aggregation in whole blood is increased in non-insulin-dependent diabetes mellitus and in female but not male patients with primary dyslipidemia. Atherosclerosis 1995; 112 (1): 115-22
27. Bröijersén A, Eriksson M, Leijd B, et al. No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17 (2): 273-8
28. Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2005; 2 (1): 16-23
29. Sudic D, Razmara M, Forslund M, et al. High glucose levels enhance platelet activation: involvement of multiple mechanisms. Br J Haematol 2006; 133 (3): 315-22
30. Ferroni P, Basili S, Falco A, et al. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 2 (8): 1282-91
31. Razmara M, Hjemdahl P, Yngen M, et al. Food intake enhances thromboxane receptor-mediated platelet activation in type 2 diabetic patients but not in healthy subjects. Diabetes Care 2007; 30 (1): 138-40
32. Boos CJ, Beevers GD, Lip GY. Assessment of platelet activation indices using the ADVIATM 120 amongst 'high-risk' patients with hypertension. Ann Med 2007; 39 (1): 72-8
33. Preston RA, Coffey JO, Materson BJ, et al. Elevated platelet P-selectin expression and platelet activation in high risk patients with uncontrolled severe hypertension. Atherosclerosis 2007; 192 (1): 148-54
34. Ebbesen LS. Hyperhomocysteinemia, thrombosis and vascular biology. Cell Mol Biol (Noisy-le-grand) 2004; 50 (8): 917-30
35. Undas A, Stepień E, Plicner D, et al. Elevated total homocysteine is associated with increased platelet activation at the site of microvascular injury: effects of folic acid administration. J Thromb Haemost 2007; 5 (5): 1070-2
36. Holven KB, Aukrust P, Pedersen TM, et al. Enhanced platelet activation in hyperhomocysteinemic individuals. J Thromb Haemost 2007; 5 (1): 193-5
37. Corica F, Corsonello A, Lucchetti M, et al. Relationship between metabolic syndrome and platelet responsiveness to leptin in overweight and obese patients. Int J Obes (Lond) 2007; 31 (5): 842-9
38. Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 2003; 163 (19): 2368-92
39. Aurigemma C, Fattorossi A, Sestito A, et al. Relationship between changes in platelet reactivity and changes in platelet receptor expression induced by physical exercise. Thromb Res 2007; 120 (6): 901-9
40. Holt RR, Actis-Goretta L, Momma TY, et al. Dietary flavanols and platelet reactivity. J Cardiovasc Pharmacol 2006; 47 Suppl. 2: S187-96
41. Pearson DA, Holt RR, Rein D, et al. Flavanols and platelet reactivity. Clin Dev Immunol 2005; 12: 1-9
42. Knapp HR. Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr 1997 May; 65 (5 Suppl.): 1687S-98S
43. Traber MG. Does vitamin E decrease heart attack risk? Summary and implications with respect to dietary recommendations. J Nutr 2001; 131 (2): 395S-7S
44. Allman-Farinelli MA, Dawson B. Diet and aging: bearing on thrombosis and hemostasis. Semin Thromb Hemost 2005; 31 (1): 111-7
45. Jackson SP. The growing complexity of platelet aggregation. Blood 2007; 15; 109 (12): 5087-95
46. Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005; 31 (4): 381-92
47. Lazarus AH, Song S, Crow AR. Understanding platelet function through signal transduction. Transfus Med Rev 2003; 17 (1): 45-56
48. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006; 99 (12): 1293-304
49. Shankar H, Kahner B, Kunapuli SP. G-protein dependent platelet signaling - perspectives for therapy. Curr Drug Targets 2006; 7 (10): 1253-63
50. Woulfe DS. Platelet G protein-coupled receptors in hemostasis and thrombosis. J Thromb Haemost 2005; 3 (10): 2193-200
51. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008; 121 (1): 43-9
52. Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007; 297 (18): 2018-24
53. De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease: an update. Stroke. Epub 2008 Feb 14
54. Costa J, Ferro JM, Matías-Guiu J, et al. Triflusal for preventing serious vascular events in people at high risk. Stroke 2006; 37: 2193-5
55. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295 (3): 306-13
56. Lotrionte M, Biondi-Zoccai GG, Agostoni P, et al. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007; 100 (8): 1199-206
57. Thompson PD, Zimet R, Forbes WP, et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002; 90 (12): 1314-9
58. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2007; (1): CD003748
59. Leonardi-Bee J, Bath PM, Bousser MG, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005; 36 (1): 162-8
60. Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 2007; 28 (4): 443-9
61. Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95 (10): 1218-22
62. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27 (22): 2667-74
63. Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation: review and meta-analysis. J Intern Med 2005; 257 (5): 399-414
64. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008 26; 336 (7637): 195-8
65. Hovens MM, Snoep JD, Eikenboom JC, et al. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007; 153 (2): 175-81
66. Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167 (15): 1593-9
67. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154 (2): 221-31
68. Purkayastha S, Athanasiou T, Malinovski V, et al. Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis. Heart 2006; 92 (4): 531-2
69. De Schryver EL, Algra A, van Gijn J. Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 2003; 34 (8): 2072-80
70. De Luca G, Suryapranata H, Stone GW, et al. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. J Am Coll Cardiol 2006; 47 (3): 685-6
71. de Queiroz Fernandes Araújo JO, Veloso HH, Braga De Paiva JM, et al. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials. Am Heart J 2004; 148 (6): 937-43
72. Kandzari DE, Hasselblad V, Tcheng JE, et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J 2004; 147 (3): 457-62
73. Hernández AV, Westerhout CM, Steyerberg EW, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. Heart 2007; 93 (4): 450-5
74. Montalescot G, Borentain M, Payot L, et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2004; 292 (3): 362-6
75. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348 (9038): 1329-39
76. Cannon CP, CAPRIE Investigators. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol 2002; 90 (7): 760-2
77. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20): 2001-15
78. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344 (25): 1888-94
79. Matías-Guiu J, Ferro JM, Alvarez-Sabín J, et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study. A randomized, double-blind, multicenter trial. Stroke 2003; 34 (4): 840-8
80. Cruz-Fernández JM, López-Bescós L, García-Dorado D, et al. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J 2000; 21 (6): 457-65
81. Culebras A, Rotta-Escalante R, Vila J, et al. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. Neurology 2004 13; 62 (7): 1073-80
82. Scrutinio D, Cimminiello C, Marubini E, et al. Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. J Am Coll Cardiol 2001; 37 (5): 1259-65
83. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 2001; 104 (5): 539-43
84. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116 (25): 2923-32
85. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111 (25): 3366-73
86. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50 (19): 1844-51
87. Bhatt DL, Topol EJ, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Executive Committee. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004 Aug; 148 (2): 263-8
88. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354 (16): 1706-17
89. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49 (19): 1982-8
90. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364 (9431): 331-7
91. ESPRIT Study Group, Halkes PH, van Gijn J, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367 (9523): 1665-73
92. Ferguson JJ. Second European Stroke Prevention Study. Circulation 1996; 93 (3): 399
93. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295 (13): 1531-8
94. Mueller C, Roskamm H, Neumann FJ, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J Am Coll Cardiol 2003; 41 (6): 969-73
95. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358 (9281): 527-33
96. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005; 111 (17): 2233-40
97. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407 (6801): 258-64
98. Leger AJ, Jacques SL, Badar J, et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 2006; 113 (9): 1244-54
99. Wu CC, Teng CM. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur J Pharmacol 2006; 546 (1-3): 142-7
100. Wu CC, Huang SW, Hwang TL, et al. YD-3, a novel inhibitor of protease-induced platelet activation. Br J Pharmacol 2000; 130 (6): 1289-96
101. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100 (9): 1261-75
102. Derian CK, Damiano BP, Addo MF, et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 2003; 304 (2): 855-61
103. Damiano BP, Derian CK, Maryanoff BE, et al. RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc Drug Rev 2003; 21 (4): 313-26
104. Johnson FL, Boyer JL, Leese PT, et al. Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589. Platelets 2007; 18 (5): 346-56
105. Wang YX, Vincelette J, da Cunha V, et al. A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. Thromb Haemost 2007; 97 (5): 847-55
106. Fiddler GI, Lumley P. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers: a review. Circulation 1990; 81 (1 Suppl.): I69-78; discussion I79-80
107. Egan KM, Wang M, Fries S, et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005; 111 (3): 334-42
108. Audoly L, Rocca B, Fabre JE, et al. Cardiovascular responses to the isoprostanes i-PF2-III and i-PE2-III are mediated via the thromboxane A2 receptor in vivo. Circulation 2000; 101 (24): 2833-40
109. Viles-Gonzalez J, Fuster V, Corti R, et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition: a magnetic resonance imaging study. Eur Heart J 2005; 26 (15): 1557-61
110. Worth N, Berry C, Thomas A, et al. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 2005; 183 (1): 65-73
111. Vilahur G, Casaní L, Badimon L. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb Haemost 2007; 98 (3): 662-9
112. Clemetson KJ, Clemetson JM. Collagen receptors as potential targets for novel anti-platelet agents. Curr Pharm Des 2007; 13 (26): 2673-83
113. Grüner S, Prostredna M, Aktas B, et al. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy. Circulation 2004; 110 (18): 2946-51
114. Grüner S, Prostredna M, Koch M, et al. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood 2005; 105 (4): 1492-9
115. Schulte V, Rabie T, Prostredna M, et al. Targeting of the collagen-binding site on glycoprotein VI is not essential for in vivo depletion of the receptor. Blood 2003; 101 (10): 3948-52
116. Yoshida S, Sudo T, Niimi M, et al. Inhibition of collagen-induced platelet aggregation by anopheline antiplatelet protein, a saliva protein from a malaria vector mosquito. Blood 2008; 111 (4): 2007-14
117. Takasaki J, Saito T, Taniguchi M, et al. A novel Galphaq/11-selective inhibitor. J Biol Chem 2004; 279 (46): 47438-45
118. Uemura T, Kawasaki T, Taniguchi M, et al. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress. Br J Pharmacol 2006; 148 (1): 61-9
119. Rieken S, Sassmann A, Herroeder S, et al. G12/G13 family G proteins regulate marginal zone B cell maturation, migration, and polarization. J Immunol 2006; 177 (5): 2985-93
120. Wettschureck N, Lee E, Libutti SK, et al. Parathyroid-specific double knockout of Gq and G11 alpha-subunits leads to a phenotype resembling germline knockout of the extracellular Ca2+-sensing receptor. Mol Endocrinol 2007; 21 (1): 274-80
121. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367 (9510): 606-17
122. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107 (23): 2908-13
123. Gurbel PA, Bliden KP, Etherington A, et al. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res 2007; 121 (1): 107-15
124. Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med 2005; 352 (3): 287-9
125. Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 2005; 95 (4): 509-10
126. Lordkipanidzé M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007 Jul; 28 (14): 1702-8
127. Rolin S, Dogne JM, Michaux C, et al. Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins Leukot Essent Fatty Acids 2001; 65 (2): 67-72
128. Cyrus T, Yao Y, Ding T, et al. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. Eur J Pharmacol 2007; 561: 105-11
129. Ghuysen A, Dogné JM, Chiap P, et al. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor. Cardiovasc Drug Rev 2005; 23: 1-14
130. Miyamoto M, Yamada N, Ikezawa S, et al. Effects of TRA-418, a novel TP-receptor antagonist, and IP-receptor agonist, on human platelet activation and aggregation. Br J Pharmacol 2003; 140 (5): 889-94
131. Lee BK, Lee SW, Park SW, et al. Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol 2007; 100 (4): 610-4
132. Spencer CG, Felmeden DC, Blann AD, et al. Effects of "newer" and "older" antihypertensive drugs on hemorrheological, platelet, and endothelial factors. A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Am J Hypertens 2007; 20 (6): 699-704
133. Skowasch D, Viktor A, Schneider-Schmitt M, et al. Differential antiplatelet effects of angiotensin converting enzyme inhibitors:comparison of ex vivo platelet aggregation in cardiovascular patients withramipril, captopril and enalapril. Clin Res Cardiol 2006; 95 (4): 212-26
134. Cha JK, Jeong MH, Kim JW. Statin reduces the platelet P-selectin expression in atherosclerotic ischemic stroke. J Thromb Thrombolysis 2004; 18 (1): 39-42
135. Muller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003; 108 (18): 2195-7
136. Ellison J, Dager W. Recent FDA warning of the concomitant use of aspirin and ibuprofen and the effects on platelet aggregation. Prev Cardiol 2007; 10 (2): 61-3
137. Teng CM, Ko FN, Wang JP, et al. Antihaemostatic and antithrombotic effect of some antiplatelet agents isolated from Chinese herbs. J Pharm Pharmacol 1991; 43 (9): 667-9
138. Chung KF, Dent G, McCusker M, et al. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet 1987; 1: 248-51
139. Jin YR, Han XH, Zhang YH, et al. 1078 Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-gamma2 phosphorylation and cyclooxygenase-1 activity. Atherosclerosis 2007; 194: 144-52
140. Yamamoto J, Yamada K, Naemura A, et al. Testing various herbs for antithrombotic effect. Nutrition 2005; 21 (5): 580-7